OREXIGEN THERAPEUTICS, Inc. (NASDAQ:OREX) Files An 8-K Entry into a Material Definitive Agreement

On March 20, 2018, Orexigen Therapeutics, Inc. (the “Company”) entered into an Instrument of Resignation, Appointment and Acceptance (the “Instrument”), with U.S. Bank National Association, as resigning trustee (the “Resigning Trustee”), and Wilmington Savings Fund Society, FSB, as successor trustee (the “Successor Trustee”).

The Instrument provides, among other things, that the Resigning Trustee confirms, assigns, transfers, delivers and conveys to the Successor Trustee all right, title, and interest of the Resigning Trustee in and to the trust created by the indenture governing the Company’s 2.75% Convertible Exchange Senior Notes due 2020 (the “Indenture”), that the Resigning Trustee resigns as Trustee, Conversion Agent, Registrar and Paying Agent, and that the Successor Trustee accepts its appointment as Trustee under the Indenture and assumes all the rights, powers, duties and obligations of the Trustee under the Indenture, and accepts its appointment as Conversion Agent, Registrar and Paying Agent under the Indenture.

The foregoing description of the Instrument does not purport to be complete and is qualified in its entirety by reference to the Instrument filed as Exhibit 4.1 hereto and incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

Orexigen Therapeutics, Inc. ExhibitEX-4.1 2 orex-ex41_6.htm EX-4.1 orex-ex41_6.htm Exhibit 4.1 EXECUTION VERSION   THIS INSTRUMENT OF RESIGNATION,…To view the full exhibit click here
About OREXIGEN THERAPEUTICS, Inc. (NASDAQ:OREX)
Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.